GENE ONLINE|News &
Opinion
Blog

2022-08-30| Trials & Approvals

Sanofi’s Treatment for Hemophilia A has a Concrete FDA Decision Date

by Max Heirich
Share To

On August 30, the United States Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for Sanofi’s efanesoctocog alfa (BIVV001) for priority review. Efanesoctocog alfa is a treatment for hemophilia A, a rare and life-threatening bleeding disorder.

Related Article: Bristol Myers Squibb’s New Drug Boasts Strong Anti-thrombotic Profile

What is efanesoctocog alfa, and how does it work?

Hemophilia A is a genetic bleeding disorder caused by a lack of Factor VIII, a blood protein. Factor VIII is a clotting factor, a specialized protein essential for normal clotting. Due to this lack of Factor VIII, individuals with hemophilia A have difficulty stopping bleeding as their wounds do not properly clot.

Current treatments for hemophilia A include methods to either replace or substitute the function of Factor VIII. An example of this is Genentech and Chugai’s HEMLIBRA. HEMLIBRA plays the part of Factor VIII as it performs its job of uniting two other proteins, Factor IXa and Factor X, inducing clotting. 

On the other hand, Sanofi’s efanesoctocog alfa works slightly differently. Efanesoctocog alfa extends the protection from bleeds through decoupling Factor VIII from von Willebrand factor (VWF) in circulation. The VWF protein helps platelets stick together and adhere to the walls of blood vessels at a wound, forming temporary clots. 

Due to promising results from a Phase 3 study, Sanofi submitted a BLA for efanesoctocog alfa to the FDA.

The Trial that the FDA Will Decide On

XTEND-1 was a Phase 3 trial evaluating the safety, efficacy, and pharmacokinetics of once-weekly efanesoctocog alfa. The study subjects were patients 12 years or older with severe hemophilia A, previously treated with factor VIII replacement therapy. The trial compared the results of efanesoctocog alfa to patients receiving their prior replacement therapy.

Sanofi presented the results of XTEND-1 at the 30th International Society of Thrombosis and Haemostasis Congress. The data showed that efanesoctocog alfa prevented bleeds superiorly than prior factor VIII replacement therapy. In addition, patients tolerated efanesoctocog alfa well. 

On the results, Dietmar Berger, MD, PhD, Global Head of Development and Chief Medical Officer at Sanofi, said, “The results from the pivotal XTEND-1 Phase 3 study demonstrate efanesoctocog alfa’s ability to reduce annualized bleeding rates, which supports its potential as a therapy with best-in-disease efficacy. We look forward to working closely with the FDA during the review process as we aim to bring this novel therapy to the hemophilia A community.”

The results of XTEND-1 formed the foundation of Sanofi’s submission for priority review. In May of this year, the FDA also granted efanesoctocog alfa its Breakthrough Therapy Designation. In addition, efanesoctocog alfa received Fast Track Designation from the FDA in 

With the data from XTEND-1 under review, the FDA plans to decide on efanesoctocog alfa’s approval by February 28, 2023. Sanofi intends to submit the treatment for hemophilia A for regulatory submission in the EU once the ongoing trial, XTEND-Kids, concludes sometime in early 2023. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
Insilico Makes its Biggest AI Deal Ever with Sanofi for Potential $1.2 Billion
2022-11-09
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!